Radiation Doses and Cancer Risks from Breast Imaging Studies

Published Online:https://doi.org/10.1148/radiol.10100570

A single breast-specific gamma imaging or positron emission mammography study is associated with a fatal radiation-induced cancer risk higher than or comparable to that of annual screening mammography in women aged 40–80 years.

Purpose

To compare radiation doses and lifetime attributable risks (LARs) of radiation-induced cancer incidence and mortality from breast imaging studies involving the use of ionizing radiation.

Materials and Methods

Recent literature on radiation doses from radiologic procedures and organ doses from nuclear medicine procedures, along with Biologic Effects of Ionizing Radiation (BEIR) VII age-dependent risk data, is used to estimate LARs of radiation-induced cancer incidence and mortality from breast imaging studies involving ionizing radiation, including screen-film mammography, digital mammography, digital breast tomosynthesis, dedicated breast computed tomography, breast-specific gamma imaging (BSGI), and positron emission mammography (PEM).

Results

Two-view digital mammography and screen-film mammography involve average mean glandular radiation doses of 3.7 and 4.7 mGy, respectively. According to BEIR VII data, these studies are associated, respectively, with LARs of fatal breast cancer of 1.3 and 1.7 cases per 100 000 women aged 40 years at exposure and less than one case per one million women aged 80 years at exposure. Annual screening digital or screen-film mammography performed in women aged 40–80 years is associated with an LAR of fatal breast cancer of 20–25 cases in 100 000. A single BSGI study involving a label-recommended dose of 740–1100 MBq (20–30 mCi) of technetium 99m–sestamibi is estimated to involve an LAR of fatal cancer that is 20–30 times that of digital mammography in women aged 40 years. A single PEM study involving a labeled dose of 370 MBq (10 mCi) of fluorine 18 fluorodeoxyglucose is estimated to involve an LAR of fatal cancer that is 23 times higher than that of digital mammography in women aged 40 years.

Conclusion

A single BSGI or PEM study is associated with a fatal radiation-induced cancer risk higher than or comparable to that of annual screening mammography in women aged 40–80 years.

© RSNA, 2010

References

  • 1 Ahmed NU, Fort J, Malin A, Hargreaves M. Barriers to mammography screening in a managed care population. Public Adm Manage 2009;13(3):7–39.
  • 2 Linton OW, Mettler FA; National Council on Radiation Protection and Measurements. National conference on dose reduction in CT, with an emphasis on pediatric patients. AJR Am J Roentgenol 2003;181(2):321–329.
  • 3 Brenner DJ, Elliston CD, Hall EJ, Berdon WE. Estimates of the cancer risks from pediatric CT radiation are not merely theoretical: comment on “point/counterpoint—in x-ray computed tomography, technique factors should be selected appropriate to patient size. against the proposition.” Med Phys 2001;28(11):2387–2388.
  • 4 Brenner DJ, Doll R, Goodhead DT, et al.. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 2003;100(24):13761–13766.
  • 5 Brenner DJ, Hall EJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med 2007;357(22):2277–2284.
  • 6 Hendrick RE, Pisano ED, Averbukh A, et al.. Comparison of acquisition parameters and breast dose in digital mammography and screen-film mammography in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial. AJR Am J Roentgenol 2010;194(2):362–369.
  • 7 Lindfors KK, Boone JM, Nelson TR, Yang K, Kwan AL, Miller DF. Dedicated breast CT: initial clinical experience. Radiology 2008;246(3):725–733.
  • 8 Poplack SP, Tosteson TD, Kogel CA, Nagy HM. Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenol 2007;189(3):616–623.
  • 9 Preston DL, Ron E, Tokuoka S, et al.. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007;168(1):1–64.
  • 10 Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors: report 13—solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003;160(4):381–407.
  • 11 Preston DL, Pierce DA, Shimizu Y, et al.. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res 2004;162(4):377–389.
  • 12 National Research Council of the National Academies. Health risks from exposure to low levels of ionizing radiation: BEIR VII, phase 2—Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Washington, DC: National Academies Press, 2006.
  • 13 International Commission on Radiological Protection. The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37(2-4):1–332.
  • 14 International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. ICRP publication 26. Ann ICRP 1977;1(3):1–53.
  • 15 International Commission on Radiological Protection. Risks associated with ionising radiations. ICRP publication SG1. Ann ICRP 1991;22(1):1–18.
  • 16 Sechopoulos I, Suryanarayanan S, Vedantham S, D’Orsi CJ, Karellas A. Radiation dose to organs and tissues from mammography: Monte Carlo and phantom study. Radiology 2008;246(2):434–443.
  • 17 Mettler FA, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008;248(1):254–263.
  • 18 Berns EA, Hendrick RE, Cutter GR. Performance comparison of full-field digital mammography to screen-film mammography in clinical practice. Med Phys 2002;29(5):830–834.
  • 19 Mettler FA, Bhargavan M, Faulkner K, et al.. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology 2009;253(2):520–531.
  • 20 Wu T, Stewart A, Stanton M, et al.. Tomographic mammography using a limited number of low-dose cone-beam projection images. Med Phys 2003;30(3):365–380.
  • 21 Boone JM, Nelson TR, Lindfors KK, Seibert JA. Dedicated breast CT: radiation dose and image quality evaluation. Radiology 2001;221(3):657–667.
  • 22 Yang WT, Carkaci S, Chen L, et al.. Dedicated cone-beam breast CT: feasibility study with surgical mastectomy specimens. AJR Am J Roentgenol 2007;189(6):1312–1315.
  • 23 Stabin MG. Doses from medical radiation sources. 2009 Health Physics Society Web site. http://www.hps.org/hpspublications/articles/dosesfrommedicalradiation.html. Accessed May 6, 2010.
  • 24 DePuey EGGarcia EVBerman DS, eds. Cardiac SPECT imaging. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2000; 119–123.
  • 25 Labeled organ doses for Miraluma (rest, 2 hour void). RxList Web site. http://www.rxlist.com/miraluma-drug.htm. Accessed May 6, 2010.
  • 26 Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009;251(1):166–174.
  • 27 Geise RA, Palchevsky A. Composition of mammographic phantom materials. Radiology 1996;198(2):347–350.
  • 28 Rosenberg RD, Yankaskas BC, Abraham LA, et al.. Performance benchmarks for screening mammography. Radiology 2006;241(1):55–66.
  • 29 National Council on Radiation Protection and Measurements. Ionizing radiation exposure of the population of the United States. NCRP report no. 160. Bethesda, Md: National Council on Radiation Protection and Measurements, 2009.
  • 30 Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004;230(1):29–41.
  • 31 Boyd NF, Guo H, Martin LJ, et al.. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356(3):227–236.
  • 32 Picano E. Informed consent and communication of risk from radiological and nuclear medicine examinations: how to escape from a communication inferno. BMJ 2004;329(7470):849–851.
  • 33 Berg WA, Weinberg IN, Narayanan D, et al.. High-resolution fluorodeoxyglucose positron emission tomography with compression (“positron emission mammography”) is highly accurate in depicting primary breast cancer. Breast J 2006;12(4):309–323.
  • 34 Brem RF, Fishman M, Rapelyea JA. Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol 2007;14(8):945–950.
  • 35 Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 2008;247(3):651–657.
  • 36 Brem RF, Ioffe M, Rapelyea JA, et al.. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol 2009;192(2):379–383.

Article History

Received March 17, 2010; revision requested April 19; revision received May 6; accepted May 14; final version accepted May 19.
Published online: Oct 2010
Published in print: Oct 2010